Aim: To investigate the performance of the Eversense XL implantable continuous glucose monitoring (CGM) system through 180 days in a primarily adolescent population with type 1 diabetes (T1D).
82% functional through day 90 and 40% functional through day 180.
The subsequent system generation included repositioning of the dexamethasone collar and updated software, and was studied in 90 adults with T1D and T2D through 90 days with a resultant MARD of 8.8%
[for blood glucose (BG) 40 to 400 mg/dL] and a 15/15% metric of 86%. 9 Ninety-one per cent of sensors were functional through day 90.
The full lifespan of the new CGM system configuration has not been fully assessed and its efficacy in a paediatric population has not yet been evaluated. This study therefore undertook the investigation of safety and effectiveness of the implantable CGM system in a primarily adolescent population with T1D for up to 180 days.
| MATERIALS AND METHODS

| Study design
The study used a non-randomized, non-blinded, prospective, singlearm, single-centre design. Subjects were ≥12 years of age and had T1D
for ≥1 year. Patients were excluded if they had any condition that might have prevented the placement or removal of the sensor, any condition that might require an MRI, or any other active implanted device.
Following an initial screening visit, subjects returned for sensor insertion followed by seven sensor accuracy assessment visits at 30 day intervals. Each sensor was inserted subcutaneously in the upper arm through a small (5-6 mm) incision which was subsequently closed with Steri-Strips. Subjects ≥18 years of age had two sensors inserted, with one designated as an unblinded (primary) sensor and the other as a blinded (secondary) sensor. Subjects <18 years of age had one sensor inserted which was unblinded. Subjects were issued an iPod to display glucose measurements from the unblinded sensor. Following the final accuracy assessment at day 180, the sensors were removed. Ten days following removal (day 190), subjects returned for follow-up and the removal site was inspected.
| Outcome measures
The primary effectiveness endpoint was MARD for all paired sensor Additional safety outcomes included insertion/removal procedure adverse events (AEs) and device-related AEs, hospitalization as a result of hypoglycaemia, hyperglycaemia or ketoacidosis, and incidence of hypoglycaemic and hyperglycaemic events occurring during home use.
| Statistical methods
To detect a difference of 4% in MARD with 80% power and a onesided significance level of 0.0250, a total of 99 independent paired glucose values are required based on one-sample t-test. Following adjustments accounting for within-subject correlation and nonnormality of ARD data, 1286 data pairs were required. At the expected 205 pairs per patient, eight enrolled subjects would be required. To ensure a robust cross-section of the target population, over the full 180-day evaluation period, and to accommodate subject dropouts over time, a target number of 36 evaluable subjects was determined. Because the sensor was not involved in subject management, the cohort expansion did not pose an additional safety concern.
The prespecified analysis population for the effectiveness endpoints was based on all evaluable glucose data from all subjects with at least one paired glucose reading. All other effectiveness analyses were evaluated using descriptive statistics. Sensor longevity was defined as the number of days between the implant and the last day the sensor remained functional, and was assessed by time-to-event analyses. Sensors which remained functional through 180 days were censored at day 180. All subjects who had a sensor placed were included in the safety analysis population.
The Kaplan-Meier method 10 was used to estimate the probability of sensor survival through 180 days, and the log-log method was used to generate 95% confidence intervals for the survival probabilities.
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Subjects in the study included adolescents and adults. While age was not expected to have an impact on device longevity, an exploratory analysis using a Cox proportional hazards model evaluated the impact of age on device longevity. MATLAB (MathWorks, Natick, Massachusetts, USA) and R version 3.4.1 (https://www.r-project.org/ about.html) were used for all statistical analyses.
The study (www.clinicaltrials.gov: NCT02933164) was performed in accordance with the Declaration of Helsinki and was approved by an ethics committee. Both written and verbal informed consent were obtained from all study subjects.
| RESULTS
A total of 36 subjects (n = 30 children; n = 6 adults) were enrolled in the study (Table 1) . Forty-three sensors were placed in the study (30 single sensor subjects, 12 bilateral dual sensor subjects and one subject who received one replacement sensor because of a suspected technical device failure). Twenty-eight subjects (78%) completed the study with day-180 data collection. Eight (22%) subjects experienced a sensor replacement alert prior to day 180 which ended glucose data collection. One subject withdrew consent because of an inability to tolerate intravenous access for in-clinic accuracy testing.
Of the subjects, 30 (83%) were youths aged 12-17 [mean (SD):
13.9 (1.4)] years and with diabetes duration of 6.0 (3.8) years. There were 6 (17%) adults with a mean age of 32.0 (15.9) and diabetes duration of 19.8 (15.5) years. Among the children, 26 (87%) were using insulin pump therapy and 17 (57%) had previously used CGM. In the adult group, all were using insulin pump therapy and all had used CGM previously. Table 1 provides a summary of demographics and baseline characteristics of the study subjects.
| Effectiveness outcomes
There were a total of 7163 matched pairs of CGM and YSI glucose readings. The primary outcome of MARD across 40 to 400 mg/dL, over the 180-day duration, was 9.4% (95% CI: 8.6%-10.5%) in the total cohort and 9.7% in the paediatric cohort (95% CI: 8.6%-10.8%).
MARD on day 1 was higher at 13.3 (13%), improving to 10.6 (10.7%)
by day 30 and then ranging between 9.1% and 9.7% over the full 180-day duration (Table A1) . CGM system agreement with YSI glucose within 15 mg/dL (<100 mg/dL) or 15% of YSI glucose values, through 60, 120 and 180 days, was 82.9%, 83.6% and 83.4%, respectively. MARD and system agreement in each successive monthly interval are shown in Table 2 .
Over the first 90 days, MARD across glycaemic ranges (Table 3) was 9.6% (9.2) in euglycaemia (71-180 mg/dL), 10.5% (8.0) in hypoglycaemia (≤70 mg/dL) and 6.7% (7.6) in hyperglycaemia (>180 mg/dL). Within each range, MARD was generally higher in the paediatric subgroup versus the adult subgroup, but the differences were not statistically significant (Table 3 ).
The surveillance error grid showed 98.4% within the green zone 99.6% of pairs in the clinically acceptable error zones of A (93.4%) and B (6.2%) ( Figure S1 , see the supporting information for this article).
The Bland-Altman analysis ( Figure S2 ) showed a non-significant bias of 2.5 mg/dL (95% CI: -32.5, 37.5) in CGM glucose compared with YSI glucose.
| Safety Outcomes
In the paediatric group, HbA1c was 8.1% ± 1.5% at baseline and slightly lower at 90 days (7.5% ± 1.1%, 58 ± 12.0 mmol/mol) and 180 days (7.9% ± 1.4%, 63 ± 15.3 mmol/mol). The adult group showed a stable HbA1c of 7.5% ± 1.0% at baseline, 7.4% ± 0.8% (57 F I G U R E 1 Surveillance error grid analysis for sensor glucose versus reference plasma glucose (Yellow Springs Instruments) ± 8.7 mmol/mol) at 90 days and 7.6% ± 0.9% (60 ± 9.8 mmol/mol) at 180 days.
T A B L E 2 Continuous glucose monitoring (CGM) system agreement with Yellow Springs Instruments (YSI) glucose within YSI glucose range 40-400 mg/dL
A total of 37 sensors implanted in 30 subjects were included in the analysis. At postimplant days 90, 120, 150 and 180, the estimated probabilities of sensor survival were 97%, 94%, 81% and 78%, respectively ( Figure S3 ).
Sensors were removed prior to 180 days for the following reasons: withdrawal of consent 1 day after insertion because of difficulty with the blood collection protocol (1); inability to maintain connection with any transmitter (2); and sensor replacement alarms at day 136 (1), day 142 (1), day 146 (3) and day 165 (1).
An exploratory Cox proportional hazards regression analysis found that subject age was not associated with sensor longevity (hazard ratio = 1.02, 95% CI = 0.94-1.10; P = 0.68).
The sensor insertion and removal procedures were well tolerated with no SAEs. The most common AEs related to the insertion/removal process were presyncope (2), nausea (2) and vomiting (2) . Sensor fracture occurred in the process of removal in two subjects without further impact.
The implanted sensor and wearable transmitter combination were also well tolerated with a median wear time of 23 ± 6.6 hours daily in the total cohort, and was not different in the paediatric cohort (23 ± 6.1 hours). Skin reactions to the sensor were mild when they occurred and included skin thinning (13), discoloration (2) and bruise (2) . One subject experienced a skin reaction to the adhesive patch which was moderate and followed a prior history of chronic dermatitis and prior intolerance of other adhesives. All skin changes resolved within 1-24 weeks of sensor removal. There were no infections.
Subjects completed two questionnaires (Tables A2 and A3 ) developed to assess the subjects' perceived impact of the CGM system and its appeal. The proportion of subjects who agreed or highly agreed that the CGM was easy to use was 82%; 90% felt that the mobile application for viewing glucose and trends was easy to use; and 87% felt confident in the alarm's reliability to warn of glucose extremes.
Regarding comfort at the sensor/transmitter site, 76% of subjects agreed or highly agreed that they had not experienced pain or discomfort when using the sensor. Ninety per cent of subjects liked the ability to see their glucose on their iPod and 82% reported actively using the glucose display at least every other hour (Table A4) . Finally, 78%
liked the longer sensor duration.
| DISCUSSION
The Our study had several limitations. Although we were able to study the CGM system in a meaningful number of adolescents, we were only able to include a small number of adults. We evaluated accuracy versus plasma glucose with multiple paired sample testing in a clinic setting but we did not manipulate plasm glucose levels to extremes, nor did we 'clamp' plasma glucose levels at specific settings. We were able to assess subjects' experience with detailed questionnaires but we did not use currently validated tools. Finally, although the skin adverse changes that occurred were mild, subjects were not assessed by a dermatologist to better define these changes.
In conclusion, the Eversense XL CGM system is safe and accurate through 180 days of sensor wear in a primarily adolescent population.
Children and adolescents face the challenge of transition to adult medical care, as well as the burden of navigating unique personal and social challenges. These challenges are reflected in their reported resistance to using devices such as CGM, in particular to wearing the device, how it will look on their body and what others will think. The high rate of daily wear and the favourable survey responses reported in this cohort suggest that the implanted Eversense sensor may be promising in its ability to potentially overcome these unique paediatric challenges. Future studies should address additional questions regarding accuracy in a larger population, in both free-living settings and in the clinic, during controlled extremes of glycaemia and in response to glucose load and to exercise.
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